PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.88%
Cash & equivalents declining -3.88% while CRVO's grows 10.41%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-3.88%
Below half of CRVO's -9.40%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.86%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-4.12%
Below half of CRVO's -9.80%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-3.46%
Both CRVO and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-3.14%
Both CRVO and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
Below half of CRVO's -9.80%. Michael Burry sees a potential red flag for stagnation or capital shortage.
36.45%
Less than half of CRVO's -4.57%. David Dodd sees a more disciplined AP approach or lower volume.
25.40%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-55.39%
Both CRVO and the company show zero Deferred Revenue (Current) Growth.
-25.40%
50-75% of CRVO's -48.55%. Bruce Berkowitz notes a more controlled liability line.
32.92%
Less than half of CRVO's -9.72%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
4.45%
Less than half of CRVO's -9.72%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.53%
≥ 1.5x CRVO's -2.02%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.86%
Similar yoy to CRVO's -9.81%. Walter Schloss sees parallel net worth trends.
-4.09%
Below half CRVO's -9.80%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.77%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
3.93%
Less than half of CRVO's -10.41%. David Dodd sees better deleveraging or stronger cash buildup than competitor.